证券代码：002262 证券简称：恩华药业 公告编号：2025-041 江苏恩华药业股份有限公司 关于董事长增持本公司股票的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚假记载、误 导性陈述或者重大遗漏承担责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 江苏恩华药业股份有限公司（以下简称"公司"或"本公司"）董事会于2025年6月17日 收到公司董事长孙彭生先生出具的《关于在二级市场增持公司股票的告知函》，董事长孙彭生 先生于2025年6月16日以自有资金通过深圳证券交易所股票交易系统以集中竞价交易方式增持 公司A股股票237,900股。现将公司董事长孙彭生先生本次增持公司股票的情况公告如下： 一、本次增持主体的基本情况 1、增持主体：孙彭生先生，男，1958年8月出生，中国国籍，无境外居留权，现任本公司 第七届董事会董事长。孙彭生先生本次增持前持有公司股份的数量为49,500,638股，占公司总 股本的比例为4.8713%。 2、相关一致行动关系持股情况 孙彭生先生与付卿先生、陈增良先生及杨自亮先生为一致行动人，对公司实行共同控制， 为本公司的实际控制人 ...

北京市立方律师事务所 关于江苏恩华药业股份有限公司 董事长增持本公司股票的 法律意见书 2025 年 6 月 北京市立方律师事务所 关于 江苏恩华药业股份有限公司董事长增持本公司股票的 法律意见书 致：江苏恩华药业股份有限公司 北京市立方律师事务所（以下简称"本所"）接受江苏恩华药业股份有限公司 （以下简称"恩华药业"或"公司"）的委托，根据《中华人民共和国证券法》（以 下简称"《证券法》"）、《上市公司收购管理办法》（以下简称"《收购办法》"）、 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作（2025 年修订）》等有关法律、法规和规范性文件的规定，以及本法律意见书出具日以前已 发生或存在的事实发表法律意见，按照律师行业公认的业务标准、道德规范和勤勉 尽责精神，就公司董事长孙彭生先生（以下简称"增持人"）于 2025 年 6 月 16 日 以自有资金通过深圳证券交易所股票交易系统以集中竞价交易方式增持公司 A 股股 票的相关事宜（以下简称"本次增持"）进行专项核查，并出具本法律意见书。 对本法律意见书，本所律师特作如下声明：本所律师依据《证券法》《律师事务 所从事证券法律业务管理办法 ...

Group 1 - The 2025 Lujiazui Forum opens today, focusing on financial reform and international cooperation to boost global economic growth [2] - The U.S. Senate passes the "Genius Act," marking a significant step in cryptocurrency legislation, aimed at clarifying regulations for digital assets [3] - The State-owned Assets Supervision and Administration Commission encourages state-owned enterprise funds to invest early and in smaller amounts to promote technological innovation [4] Group 2 - Major banks are discontinuing long-term large-denomination certificates of deposit (CDs) as interest rates decline, with the maximum term now being two years [5] - The Israeli ambassador to the U.S. requests a defensive posture from the U.S. amid rising tensions with Iran, with oil prices potentially soaring to $120 [6] - Multiple listed companies have announced share buyback plans, with a total of 71.71 billion yuan in buybacks reported this year [8] Group 3 - The STAR Market's index has seen a decline, with technology stocks experiencing significant pullbacks, while defense and power equipment stocks have shown resilience [9] - Dividend-themed funds are gaining traction as safe-haven investments, with several ETFs reaching new highs in share volume [10] - The G7 summit discussions between the U.S. and Japan did not yield an agreement on tariff cancellations, indicating ongoing trade negotiations [11] Group 4 - JD.com's chairman Liu Qiangdong elaborates on the company's strategy, emphasizing supply chain management and local e-commerce for international business [12] - Hezhang Technology's profit forecast has drastically changed, with a reported net loss of 5.636 million yuan, reflecting internal control deficiencies [13] - The market is witnessing a surge in interest for brain-computer interface technology, with several companies reporting significant stock price increases [16] Group 5 - National Electric Power's subsidiaries have won contracts totaling 1.061 billion yuan for power cable projects, representing 19.29% of the company's projected annual revenue [28]

Core Viewpoint - Multiple companies in the Shanghai and Shenzhen stock markets have announced significant developments, including acquisitions, new product launches, and changes in management, which may present investment opportunities and risks for investors [2] Group 1: Major Announcements - BOE Technology Group plans to acquire a 30% stake in Rainbow Optoelectronics for a base price of 4.849 billion yuan, aiming to enhance its competitive edge [3] - Taihe Intelligent intends to acquire 100% of Sunshine Yuchu for 45.8 million yuan, with the transaction being an affiliated deal [5][6] - Guoxin Technology successfully tested a new quantum-resistant encryption card, which combines quantum-resistant algorithms with traditional national encryption algorithms [7] Group 2: Stock Performance and Risks - Dongxin Peace reported a significant stock price increase of over 20% in two consecutive trading days, while acknowledging uncertainties in its blockchain and digital wallet projects [4] - Huayang New Materials warned of irrational speculation risks due to significant stock price fluctuations, clarifying that it does not possess rare earth permanent magnet attributes [8] Group 3: Management Changes - Guodian Nanrui elected Zheng Zongqiang as the chairman of its board of directors [9] - Daqin Railway appointed Zhang Hongyi as the new general manager following the retirement of the previous manager [10] Group 4: Financial Performance - Jingyi Equipment expects a revenue increase of 36.54% to 42.48% year-on-year for the first half of 2025, projecting revenue between 690 million and 720 million yuan [11] Group 5: Shareholding Changes - Enhua Pharmaceutical's chairman increased his stake by purchasing 237,900 shares, which will not affect the company's control or governance structure [12] - Yunlu Co. plans for its executives to collectively increase their holdings by 4 million to 12 million yuan within six months [13][14] Group 6: Share Buybacks - Guangda Special Materials' chairman proposed a share buyback plan with a total amount between 200 million and 400 million yuan to support employee stock ownership plans or convertible bonds [15] Group 7: Major Contracts - Zhongchao Holdings announced that its subsidiaries won multiple power cable projects with a total bid amount of 1.061 billion yuan, representing 19.29% of the company's audited revenue for 2024 [16]

Group 1 - Company Xi Zhong Technology proposed to repurchase shares worth between 75 million and 150 million yuan using excess funds and self-owned funds [1] - Company Yongxi Electronics expects a revenue growth of 16.6% to 28.88% in the first half of the year, with projected revenue between 1.9 billion and 2.1 billion yuan [2] - Company Jingyi Equipment anticipates a revenue increase of 36.54% to 42.48%, with expected revenue between 690 million and 720 million yuan [2][3] Group 2 - Company Haipuri received approval from the European Medicines Agency (EMA) for a new production line for Enoxaparin Sodium injection, with an annual capacity of 330 million doses [4] - Company Inner Mongolia Xinhua plans to merge its wholly-owned subsidiaries to optimize resource allocation and improve operational efficiency [5] - Company Cloud Chemical intends to sign daily related transaction framework agreements with its controlling shareholder to reduce operational costs [7] Group 3 - Company China Software received approval from the China Securities Regulatory Commission for a specific stock issuance [8] - Company Wankong Intelligent's subsidiary won a bid for a project with the State Grid worth approximately 12.17 million yuan [9] - Company Lianlong obtained a patent for an anti-aging agent, which is expected to enhance its product offerings in polymer materials [11] Group 4 - Company Yunlu plans to increase its shares by 4 million to 12 million yuan through stock purchases by its executives [12] - Company Enhua Pharmaceutical's chairman increased his stake by 237,900 shares [14] - Company Daqin Railway announced the resignation of its general manager due to retirement [15] Group 5 - Company Hefei Urban Construction signed a land use rights transfer contract for an industrial site with an area of 78,561.78 square meters, with a payment of 103 million yuan due by July 13, 2025 [16] - Company Taiji Group received a government subsidy of 20 million yuan, representing 75.04% of its projected net profit for 2024 [17] - Company Guodian Nanrui elected a new chairman, Zheng Zongqiang, while he resigned from his previous roles [19] Group 6 - Company Xinhua Medical received a medical device registration certificate for a thromboelastography testing kit [20] - Company Baotailong's subsidiary obtained a mining license for a graphite mine with a production capacity of 2 million tons per year [21] - Company Zejing Pharmaceutical received approval for clinical trials of its innovative cancer treatment drugs [22] Group 7 - Company Aojing Medical's artificial bone repair material received registration approval in Vietnam [23] - Company Chengjian Development received a cash dividend of 90.2169 million yuan from Guoxin Securities [24] - Company Rili Technology proposed a share repurchase plan worth between 10 million and 20 million yuan [25] Group 8 - Company Deshi General Institute received approval to issue up to 1 billion yuan in technology innovation bonds [44] - Company Tongding Interconnect plans to bid for two procurement projects worth approximately 717 million yuan [46] - Company Bangji Technology plans to acquire multiple agricultural companies [46]

Group 1 - Guoxin Technology successfully tested its new quantum-resistant password card product CCUPHPQ01, which combines quantum-resistant algorithms with classical national encryption algorithms [3] - The product supports various national encryption algorithms such as SM1, SM2, SM3, SM4, and mainstream quantum-resistant algorithms like Kyber and Dilithium [3] - Guoxin Technology has sent samples to multiple clients, who are developing information security applications based on the new product [3] Group 2 - Huayang New Materials issued a risk warning regarding irrational speculation, clarifying that it does not possess rare earth permanent magnet attributes and its main business is precious metal recycling [4] - The company noted significant stock price fluctuations, with a cumulative increase that deviated from the industry average, indicating potential irrational market behavior [4] - Huayang New Materials faces rising raw material procurement costs due to increasing precious metal prices [4] Group 3 - Guodian Nanrui elected Zheng Zongqiang as the chairman of its ninth board of directors [5] - Daqin Railway appointed Zhang Hongyi as the new general manager following the retirement of the previous general manager [6] Group 4 - Jingyi Equipment expects a year-on-year revenue increase of 36.54% to 42.48%, projecting revenue between 690 million to 720 million yuan for the first half of 2025 [8] Group 5 - Enhua Pharmaceutical's chairman, Sun Pengsheng, increased his stake by purchasing 237,900 shares of the company [10] - Yunlu Co., Ltd. announced that its directors and senior management plan to collectively increase their holdings by 4 million to 12 million yuan [11][12] Group 6 - Guoda Special Materials' chairman proposed a share buyback plan with a total amount between 200 million to 400 million yuan [14] Group 7 - Zhongchao Holdings' subsidiaries won multiple power cable projects with a total bid amount of 1.061 billion yuan, representing 19.29% of the company's audited revenue for 2024 [16]

北京市立方律师事务所 关于江苏恩华药业股份有限公司 董事长增持本公司股票的 法律意见书 北京市立方律师事务所 关于 江苏恩华药业股份有限公司董事长增持本公司股票的 法律意见书 致：江苏恩华药业股份有限公司 北京市立方律师事务所（以下简称"本所"）接受江苏恩华药业股份有限公司 （以下简称"恩华药业"或"公司"）的委托，根据《中华人民共和国证券法》（以 下简称"《证券法》"）、《上市公司收购管理办法》（以下简称"《收购办法》"）、 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作（2025 年修订）》等有关法律、法规和规范性文件的规定，以及本法律意见书出具日以前已 发生或存在的事实发表法律意见，按照律师行业公认的业务标准、道德规范和勤勉 尽责精神，就公司董事长孙彭生先生（以下简称"增持人"）于 2025 年 6 月 16 日 以自有资金通过深圳证券交易所股票交易系统以集中竞价交易方式增持公司 A 股股 票的相关事宜（以下简称"本次增持"）进行专项核查，并出具本法律意见书。 对本法律意见书，本所律师特作如下声明：本所律师依据《证券法》《律师事务 所从事证券法律业务管理办法》和《律师事务所证券法 ...

Group 1 - The company held its seventh board meeting and supervisory board meeting on May 27, 2025, where it approved the proposal to repurchase and cancel part of the restricted stock [1] - The company will repurchase 390,209 shares of restricted stock at a price of 11.15 yuan per share, totaling 4,350,830.35 yuan [1] - After the repurchase and cancellation, the company's registered capital will decrease from 1,016,176,792 yuan to 1,015,786,583 yuan [1] Group 2 - The company notified creditors that they have 45 days from the announcement date to request debt repayment or guarantees [2] - Creditors must submit written requests along with relevant proof documents to the company [2] - The announcement provides contact details for the finance department for creditors to submit their claims [2]

Core Viewpoint - The legal opinion issued by Beijing Lifang Law Firm confirms the legality and validity of the procedures and results of Jiangsu Enhua Pharmaceutical Co., Ltd.'s 2025 first extraordinary general meeting of shareholders [1][6]. Group 1: Meeting Procedures - The extraordinary general meeting was convened by the second meeting of the seventh board of directors on May 27, 2025, and the notice was published on May 28, 2025 [2][3]. - The notice included details about the meeting's time, location, voting rights, and registration methods for shareholders [3][4]. - The meeting was held on June 13, 2025, combining on-site voting and online voting through the Shenzhen Stock Exchange trading system [3][4]. Group 2: Participant Qualifications - A total of 353 participants attended the meeting, representing 487,253,371 shares, which is 5.1838% of the total voting shares [4][5]. - The qualifications of the shareholders and their representatives were verified and deemed valid [5][6]. Group 3: Voting Procedures and Results - The voting was conducted through a combination of on-site and online methods, with the results aligning with the previously announced agenda [5][6]. - The meeting's resolutions required a two-thirds majority approval from the attending shareholders for special resolutions [6].

Meeting Details - The shareholders' meeting of Jiangsu Enhua Pharmaceutical Co., Ltd. was held on June 13, 2025, at 9:00 AM [1] - The meeting combined on-site voting and online voting, with specific voting times outlined for both methods [1] - The meeting was convened by the board of directors and presided over by Chairman Sun Pengsheng [1] Attendance and Voting - A total of 353 participants attended the meeting, representing 539,930,290 shares, which is 53.1335% of the total voting shares [2] - Among the attendees, 6 participated on-site, representing 487,253,371 shares (47.9497% of total voting shares), while 347 participated via online voting [2] - Small and medium investors accounted for 52,943,719 shares, or 5.2101% of the total voting shares [2] Proposal Voting Results - The meeting approved a proposal regarding the repurchase and cancellation of restricted stock, with all involved parties abstaining from voting [3] - The proposal required a two-thirds majority of the valid voting rights present at the meeting to pass, which was achieved [4] Legal Opinion - The meeting was witnessed by lawyers from Beijing Lifang Law Firm, who confirmed that the convening and voting procedures complied with relevant laws and regulations [4]